Alivus Life Sciences [GLS] vs Granules India [GRANULES] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Alivus Life Sciences Ltd. wins in 7 metrics, Granules India Ltd. wins in 11 metrics, with 0 ties. Granules India Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Alivus Life Sciences Ltd. | Granules India Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 31.45 | 29.90 | Granules India Ltd. |
| Price-to-Book Ratio | 4.87 | 4.10 | Granules India Ltd. |
| Debt-to-Equity Ratio | 0.01 | 45.37 | Alivus Life Sciences Ltd. |
| PEG Ratio | 2.05 | 1.08 | Granules India Ltd. |
| EV/EBITDA | 17.60 | 16.93 | Granules India Ltd. |
| Profit Margin (TTM) | 53.28% | 10.71% | Alivus Life Sciences Ltd. |
| Operating Margin (TTM) | 28.97% | 16.90% | Alivus Life Sciences Ltd. |
| EBITDA Margin (TTM) | 28.97% | 16.90% | Alivus Life Sciences Ltd. |
| Return on Equity | 20.19% | 13.50% | Alivus Life Sciences Ltd. |
| Return on Assets (TTM) | 16.52% | 8.02% | Alivus Life Sciences Ltd. |
| Free Cash Flow (TTM) | $2.85B | $2.95B | Granules India Ltd. |
| Dividend Yield | N/A | 0.30% | N/A |
| 1-Year Return | 1.86% | 50.46% | Granules India Ltd. |
| Price-to-Sales Ratio (TTM) | 5.66 | 3.27 | Granules India Ltd. |
| Enterprise Value | $120.91B | $173.92B | Granules India Ltd. |
| EV/Revenue Ratio | 5.53 | 3.42 | Granules India Ltd. |
| Gross Profit Margin (TTM) | 55.55% | 63.60% | Granules India Ltd. |
| Revenue per Share (TTM) | $178 | $210 | Granules India Ltd. |
| Earnings per Share (Diluted) | $38.38 | $22.50 | Alivus Life Sciences Ltd. |
| Beta (Stock Volatility) | N/A | -0.08 | N/A |
Alivus Life Sciences Ltd. vs Granules India Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Alivus Life Sciences Ltd. | 1.51% | 5.94% | 1.62% | 14.70% | 16.55% | 16.96% |
| Granules India Ltd. | -2.34% | -2.33% | 1.67% | 32.01% | 30.95% | 20.88% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Alivus Life Sciences Ltd. | 1.86% | 71.75% | 38.02% | 38.02% | 38.02% | 38.02% |
| Granules India Ltd. | 50.46% | 162.44% | 146.61% | 452.60% | 8,639.45% | 8,917.06% |
Performance & Financial Health Analysis: Alivus Life Sciences Ltd. vs Granules India Ltd.
| Metric | GLS | GRANULES |
|---|---|---|
| Market Information | ||
| Market Cap | ₹123.75B | ₹170.22B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 92,971 | 1,262,375 |
| 90 Day Avg. Volume | 72,770 | 1,054,744 |
| Last Close | ₹1,061.50 | ₹748.50 |
| 52 Week Range | ₹819.00 - ₹1,148.40 | ₹432.60 - ₹804.30 |
| % from 52W High | -7.57% | -6.94% |
| All-Time High | ₹1,335.10 (Sep 16, 2024) | ₹804.30 (May 29, 2026) |
| % from All-Time High | -20.49% | -6.94% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.27% | 0.22% |
| Quarterly Earnings Growth | 0.12% | 0.28% |
| Financial Health | ||
| Profit Margin (TTM) | 0.53% | 0.11% |
| Operating Margin (TTM) | 0.29% | 0.17% |
| Return on Equity (TTM) | 0.20% | 0.14% |
| Debt to Equity (MRQ) | 0.01 | 45.37 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹207.22 | ₹164.06 |
| Cash per Share (MRQ) | N/A | ₹25.51 |
| Operating Cash Flow (TTM) | ₹4.70B | ₹7.56B |
| Levered Free Cash Flow (TTM) | ₹4.71B | ₹5.02B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.30% |
| Last 12-Month Dividend | ₹0.00 | ₹1.50 |
Valuation & Enterprise Metrics Analysis: Alivus Life Sciences Ltd. vs Granules India Ltd.
| Metric | GLS (Apr 07, 2026) | GRANULES (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 31.45 | 29.90 |
| Forward P/E | 22.31 | 22.35 |
| PEG Ratio | 2.05 | 1.08 |
| Price to Sales (TTM) | 5.66 | 3.27 |
| Price to Book (MRQ) | 4.87 | 4.10 |
| Market Capitalization | ||
| Market Capitalization | ₹123.75B | ₹170.22B |
| Enterprise Value | ₹120.91B | ₹173.92B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.53 | 3.42 |
| Enterprise to EBITDA | 17.60 | 16.93 |
| Risk & Other Metrics | ||
| Beta | N/A | -0.08 |
| Book Value per Share (MRQ) | ₹207.22 | ₹164.06 |
Financial Statements Comparison: Alivus Life Sciences Ltd. vs Granules India Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | GLS (2024) | GRANULES (2025) |
|---|---|---|
| Revenue/Sales | 21.85B | 44.56B |
| Cost of Goods Sold | 10.21B | 18.34B |
| COGS % of Revenue | 46.7% | 41.1% |
| Gross Profit | 11.64B | 26.22B |
| Gross Margin | 53.3% | 58.9% |
| Research & Development | N/A | 2.38B |
| Operating Income (EBIT) | 6.22B | 7.29B |
| Operating Margin | 28.5% | 16.4% |
| EBITDA | 6.87B | 9.25B |
| EBITDA Margin | 31.4% | 20.8% |
| Pre-Tax Income | 6.31B | 6.60B |
| Pre-Tax Income % of Revenue | 28.9% | 14.8% |
| Income Tax | 1.60B | 1.59B |
| Income Tax % of Revenue | 7.3% | 3.6% |
| Net Income (Profit) | 4.71B | 5.02B |
| Profit Margin | 21.6% | 11.3% |
Balance Sheet & Liquidity Metrics
| Metric | GLS (2024) | GRANULES (2025) |
|---|---|---|
| Cash & Equivalents | 3.01B | 4.66B |
| Total Current Assets | 19.16B | 31.15B |
| Total Current Assets % of Revenue | 87.7% | 69.9% |
| Total Current Liabilities | 4.39B | 20.03B |
| Total Current Liabilities % of Revenue | 20.1% | 45.0% |
| Long-Term Debt | 147.61M | 4.71B |
| Long-Term Debt % of Revenue | 0.7% | 10.6% |
| Total Shareholders Equity | 23.32B | 37.16B |
| Retained Earnings | 12.92B | 30.59B |
| Retained Earnings % of Revenue | 59.1% | 68.7% |
| Property, Plant & Equipment | 7.95B | 719.13M |
Cash Flow Statement Comparison
| Metric | GLS (2024) | GRANULES (2025) |
|---|---|---|
| Operating Cash Flow | 4.70B | 7.56B |
| Operating Cash Flow % of Revenue | 21.5% | 17.0% |
| Capital Expenditures | -1.29B | -5.70B |
| Free Cash Flow | 2.85B | 2.95B |
| FCF Margin | 13.0% | 6.6% |
| Debt Repayment | N/A | -23.41B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GLS | GRANULES |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 122.53M | 247.80M |
| Float Shares | N/A | 147.11M |
| % Held by Insiders | N/A | 39.31% |
| % Held by Institutions | N/A | 23.27% |
| % Held by Public | N/A | 37.42% |
Dividend Analysis & Yield Comparison: Alivus Life Sciences Ltd. vs Granules India Ltd.
| Metric | GLS | GRANULES |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹1.50 |
| Last 12-Month Dividend Yield | N/A | 0.30% |
| 3-Year Avg Annual Dividend | ₹18.00 | ₹1.50 |
| 3-Year Avg Dividend Yield | 3.82% | 0.33% |
| 3-Year Total Dividends | ₹54.00 | ₹4.50 |
| Ex-Dividend Date | Oct 17, 2023 | Jul 31, 2025 |